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SuƌǀeyiŶg patieŶts͛ ǀieǁs oŶ tƌial iŶfoƌŵatioŶ pƌoǀisioŶ aŶd decisioŶ ŵakiŶg using the 
͚Accept/DecliŶe͛ cliŶical tƌials ƋuestioŶŶaiƌe 
Kathryn Monson1, Tom Treasure2, Chris Brew-Graves3, Valerie Jenkins1, Lesley Fallowfield 
1Sussex Health Outcomes Research & Education in Cancer, Brighton & Sussex Medical School, 
University of Sussex, 2Clinical Operational Research Unit, University College London, 3Surgical & 
Interventional Trials Unit, University College London 
Introduction: The Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) trial completed its 
feasibility phase in 2015. Surgically treated colorectal cancer patients, with newly diagnosed lung 
metastases, were randomised to continued active monitoring or pulmonary metastasectomy 
followed by active monitoring.  Randomisation was a two stage process; Stage 1 investigations 
assessed fitness for surgery and eligibility for Stage 2 randomisation. A key trial criterion was 
clinician uncertainty regarding the benefit of surgery iŶ the light of the patieŶt͛s test ƌesults.  The 
trial was anticipated to be challenging for both clinicians and patients. Both patient information, and 
healthcare professional, training DVDs were produced to assist with trial discussions and decision 
making. Additionally a patient survey was conducted to eǆaŵiŶe patieŶts͛ ǀieǁs about the trial. 
Method:  Following PulMiCC stage 1 tests, patients eligible for randomisation (PulMiCC stage 2) were 
offered an ͚AĐĐept/DeĐliŶe͛ ƋuestioŶŶaiƌe to complete following their decision to either proceed to 
randomisation or decline PulMiCC stage 2. This 16 item, Likert scale, self-report questionnaire 
eǆploƌes aspeĐts of tƌial iŶfoƌŵatioŶ pƌoǀisioŶ, patieŶts͛ ĐoŶĐeƌŶs aďout theiƌ illŶess, iŶflueŶĐe of 
friends, family and doctor, and concerns regarding randomisation (V Jenkins, L Fallowfield, 2000). It 
eŶaďles the ĐolleĐtioŶ of patieŶts͛ ǀieǁs oŶ keǇ issues suƌƌouŶdiŶg tƌial iŶformation provision and 
decision-making in a structured, quantitative manner.  Patients also identify their most important 
reason for accepting or declining study participation.  The questions are worded generically to 
enable widespread use in randomised trials.  
Results:  Questionnaires were returned by 54 randomised patients and 57 who declined 
randomisation. The majority 106/111 (95%) indicated that they had received sufficient written 
information about the study and 110/111 (99%) indicated that the doctor had told them what they 
needed to know about the trial.  Of patients who agreed to randomisation, 43/54 (80%) thought the 
trial offered the best treatment available and 48/54 (89%) were satisfied that either treatment in the 
trial would be suitable for them. Twenty five patients (44%) who declined randomisation were 
satisfied that either treatment in the trial would be suitable for them but 40/57 (70%) wanted the 
doctor to choose their treatment rather than be randomised by a computer. The results did not 
highlight significant problems such as patients feeling uŶaďle to saǇ ͚No͛ oƌ ĐoŶĐeƌŶs that their illness 
might get worse unless they joined the study.   We have been able to use the information, together 
ǁith ĐliŶiĐiaŶs͛ ǀieǁs oŶ theiƌ eǆpeƌieŶĐes of the feasiďilitǇ phase of the trial, to identify potential 
barriers to recruitment and enable strategies to be put in place to address these. 
Conclusion:  We found the questionnaire easy to administer and acceptable to both patients who 
declined or agreed to join PulMiCC stage 2.  It is an efficient tool for collecting relevant views from 
patients regarding potential drivers and barriers to recruitment.  
 
 
 
